A Phase II Study Assessing the Effect of Pembrolizumab Induced Changes to the NK Cell Exhaustion Phenotype on the Efficacy of PD-1 Targeted Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- Acronyms Merck NK-IIT
- 02 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 13 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Aug 2017 New trial record